RE:RE:90, 180, 360.... CR% the same. Gojotv! said:
"As far as I'm concerned, anything over 30% CR is very exciting.
For the purposes of this trial, only two treatments were given per patient.
That makes sense, because you want to test over a broad cross-section of people, and keep trial costs down.
But in the real world, with TLD-1433's negligible side effects, you can just keep treating... 3, 4 times... until it works.
We're looking at the cure for cancer here, folks.
The science is one thing (and very exciting science it is) but the practical application opens up a world of possibility."
Well said gojo....
The two treatment protocol isn't set in stone in the practical world. A reinduction treatment with or without a second treatment could potentially be performed for patients with a later-onset recurrence...imo.
The historical CR rates of the FDA-approved drugs, Keytruda & Valrubicin, are 41% & 18% respectively, which sets a pretty low threshold to overcome. The bar gets even lower when looking at their durable response rates...with Keytruda at 19%.
A competitor combination treatment that is still under investigation (which combines N-803 + BCG & is instilled in the bladder) looks promising, but requires a minimum 20+ treatments (including induction + maintenance treatments) in the first 18 months...& that's if all goes well (I.e. no need for a reinduction treatment, which would be 6 added instillations).
With TLT's safety profile, significantly fewer required treatments, durable response signals obtained thus far & novel mechanism of action, I agree that a CR rate of 30+% would be exciting & sufficient. However, the optimized data to date is proving far more promising...let's hope that trend continues . Also, can't forget we are also at a 67% durable response rate to date (2/3) at 730 days & counting...after having received a "single" treatment : ). Now that's exciting! Keeping the faith in this tech. Good luck...